Nedocromil: Indication, Dosage, Side Effect, Precaution

Generic Medicine Info Patient Medicine Information

This information is not country-specific. Please refer to the Malaysia prescribing information.

Generic Medicine Info

Indications and Dosage

Inhalation/Respiratory
Chronic asthma

Adult: As metered-dose inhaler (2 mg/dose): Initially, 2 actuations 4 times daily. Dose may be reduced to bid, according to patient’s response.
Child: ≥6 yr Same as adult dose.

Ophthalmic
Vernal keratoconjunctivitis

Adult: As 2% soln: Instill 1 drop into each eye 4 times daily.
Child: ≥6 yr Same as adult dose.

Ophthalmic
Allergic conjunctivitis

Adult: As 2% soln: Instill 1-2 drop into each eye bid, may be increased to 4 times daily, if necessary. Max treatment duration: 12 wk.
Child: ≥6 yr Same as adult dose.

Special Precautions

Not intended for use in acute asthma attack. Avoid abrupt withdrawal. Childn. Pregnancy and lactation.

Adverse Reactions

Nervous: Headache.
GI: Nausea, vomiting, abdominal pain, dysgeusia, dyspepsia.
Resp: Cough, throat irritation, transient bronchospasm, pharyngitis, nasal congestion, rhinitis.
Ophthalmologic: Burning, irritation, stinging, conjunctivitis, eye redness, photophobia.

Pregnancy Category (US FDA)

Inhalation/Respiratory/Ophth: B

Patient Counseling Information

Remove contact lenses prior to ophth admin and reinsert after 10-15 min.

Action

Description:
Mechanism of Action: Nedocromil is a pyranoquinoline dicarboxylic acid derivative, a mast- cell stabiliser. It suppresses immediate and delayed allergic reaction by inhibiting activation of eosinophils and release of inflammatory chemotactic and smooth muscle contracting mediators (e.g. histamine, leukotrienes, prostaglandin), thus reduces bronchospasm, cough and bronchial hyperreactivity, improves measurements of lung function, and provides relief from ocular itching associated w/ allergic conjunctivitis.
Pharmacokinetics:
Absorption: Approx 5 % is absorbed from the resp tract (inhalation). <4% is absorbed systemically (ophth). Time to peak plasma concentration: W/in 1 hr.
Distribution: Plasma protein binding: Approx 89%.
Excretion: Mainly via urine (70%, as unchanged drug); faeces (30%, as unchanged drug). Elimination half-life: Approx 1-3.3 hr.

Chemical Structure

Storage

Ophth: Store below 25°C. Inhalation: Store below 30°C. Protect from direct sunlight.

MIMS Class

Antiasthmatic & COPD Preparations / Ophthalmic Decongestants, Anesthetics, Anti-Inflammatories

ATC Classification

R03BC03 - nedocromil ; Belongs to the class of other inhalants used in the treatment of obstructive airway diseases, antiallergic agents.
S01GX04 - nedocromil ; Belongs to the class of other ophthalmologic antiallergics.

References

Alocril Solution/Spray (Allergan, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 02/10/2017.

Anon. Nedocromil. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 02/10/2017.

Buckingham R (ed). Nedocromil Sodium. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 02/10/2017.

Joint Formulary Committee. Nedocromil Sodium. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 02/10/2017.

McEvoy GK, Snow EK, Miller J et al (eds). Nedocromil (EENT). AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 02/10/2017.

Disclaimer: This information is independently developed by MIMS based on Nedocromil from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com